Summarized by Masters of Longevity from PR Newswire.
FCS investigators presented first‑in‑human and early clinical trial findings on RAS‑targeted agents.

Key Takeaways
- FCS investigators were involved in first‑in‑human KRAS inhibitor trials.
- Preliminary phase 1 results were reported for an EGFR‑HER3 bispecific ADC.
- Statewide partnerships have expanded patient access to early trials.



